About Cytochrome P450 2F1
Cytochrome P450 2F1 (CYP2F1) is a protein
from Homo sapiens identified by UniProt accession
P24903, 491 residues long.
MolForge cross-references it against 0 known binders and
33 disease associations.
Target properties
| Protein name | Cytochrome P450 2F1 |
| UniProt accession | P24903 |
| Gene | CYP2F1 |
| Organism | Homo sapiens |
| Length | 491 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (33)
Diseases linked to this target (Open Targets).
- cutaneous melanoma · score 0.23
- glioblastoma multiforme · score 0.22
- lung adenocarcinoma · score 0.21
- endometrial cancer · score 0.16
- urinary bladder cancer · score 0.13
- head and neck squamous cell carcinoma · score 0.10
- glycoprotein storage disease · score 0.05
- hemoglobin H disease · score 0.04
- hemoglobin C-beta-thalassemia syndrome · score 0.04
- combined immunodeficiency due to OX40 deficiency · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P24903-F1 | alphafold | PREDICTED | 93.19 | — |
Amino-acid sequence (491 residues)
MDSISTAILL LLLALVCLLL TLSSRDKGKL PPGPRPLSIL GNLLLLCSQD MLTSLTKLSK EYGSMYTVHL GPRRVVVLSG YQAVKEALVD QGEEFSGRGD YPAFFNFTKG NGIAFSSGDR WKVLRQFSIQ ILRNFGMGKR SIEERILEEG SFLLAELRKT EGEPFDPTFV LSRSVSNIIC SVLFGSRFDY DDERLLTIIR LINDNFQIMS SPWGELYDIF PSLLDWVPGP HQRIFQNFKC LRDLIAHSVH DHQASLDPRS PRDFIQCFLT KMAEEKEDPL SHFHMDTLLM TTHNLLFGGT KTVSTTLHHA FLALMKYPKV QARVQEEIDL VVGRARLPAL KDRAAMPYTD AVIHEVQRFA DIIPMNLPHR VTRDTAFRGF LIPKGTDVIT LLNTVHYDPS QFLTPQEFNP EHFLDANQSF KKSPAFMPFS AGRRLCLGES LARMELFLYL TAILQSFSLQ PLGAPEDIDL TPLSSGLGNL PRPFQLCLRP R
Explore Cytochrome P450 2F1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets